Escherichia coli Nissle 1917 Targets and Restrains Mouse B16 Melanoma and 4T1 Breast Tumors through Expression of Azurin Protein
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
Many studies have demonstrated that intravenously administered bacteria can target and proliferate in solid tumors and then quickly be released from other organs. Here, we employed the tumor-targeting property of Escherichia coli Nissle 1917 to inhibit mouse B16 melanoma and 4T1 breast tumors through the expression of azurin protein. For this purpose, recombinant azurin-expressing E. coli Nissle 1917 was developed. The levels of in vitro and in vivo azurin secretion in the engineered bacterium were determined by immunochemistry. Our results demonstrated that B16 melanoma and orthotopic 4T1 breast tumor growth were remarkably restrained and pulmonary metastasis was prevented in immunocompetent mice. It is worth noting that this therapeutic effect partially resulted from the antitumor activity of neutrophils and lymphocytes due to inflammatory responses caused by bacterial infections. No toxicity was observed in the animal during the experiments. This study indicates that E. coli Nissle 1917 could be a potential carrier to deliver antitumor drugs effectively for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, E. coli has been shown to colonize the region surrounding the necrotic core of tumors after intravenous injection9, and several reports have demonstrated the use of engineered E. coli strains to treat solid tumors in preclinical models15,62–65.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [63]
In the citing paper
“Zhang et al. developed a strain of EcN to express azurin, a small bacterial protein that induces apoptosis in tumor cells62. This engineered strain suppressed the growth of tumors and prevented pulmonary metastasis in mice63.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Probiotics, Prebiotics, and Synbiotics
de Vrese, M., & Schrezenmeir, J. (2008) · Advances in Biochemical Engineering/Biotechnology · doi:10.1007/10_2008_097 · Cited by 1,028
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614
Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
Wiemann, B., & Starnes, C. O. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90023-x · Cited by 467
Probiotics, Prebiotics and Synbiotics
Hawrelak, J. (2007) · eCite Digital Repository (University of Tasmania) · Cited by 320
Zhao, M., Yang, M., Ma, H., Li, X., Tan, X., Li, S., Yang, Z., & Hoffman, R. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0716 · Cited by 305
Bacteriolytic therapy can generate a potent immune response against experimental tumors
Agrawal, N., Bettegowda, C., Cheong, I., Geschwind, J.-F., Drake, C. G., Hipkiss, E. L., Tatsumi, M., Dang, L. H., Diaz, L. A., Pomper, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406242101 · Cited by 304
Short hairpin RNA–expressing bacteria elicit RNA interference in mammals
Xiang, S., Fruehauf, J., & Li, C. J. (2006) · Nature Biotechnology · doi:10.1038/nbt1211 · Cited by 271
Stritzker, J., Weibel, S., Hill, P. J., Oelschlaeger, T. A., Goebel, W., & Szalay, A. A. (2007) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2007.01.008 · Cited by 224
Henker, J., Laass, M., Blokhin, B. M., Bolbot, Y. K., Maydannik, V. G., Elze, M., Wolff, C., & Schulze, J. (2007) · European Journal of Pediatrics · doi:10.1007/s00431-007-0419-x · Cited by 199
Noncationic Peptides Obtained From Azurin Preferentially Enter Cancer Cells
Taylor, B. N., Mehta, R. R., Yamada, T., Lekmine, F., Christov, K., Chakrabarty, A. M., Green, A., Bratescu, L., Shilkaitis, A., Beattie, C. W., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2932 · Cited by 184
Cited by
Items 101–138 of 138
Madsen, C. S., Makela, A. V., Maduka, C. V., Greeson, E. M., Tundo, A., Ural, E. E., Kulkarni, S. H., Zarea, A. A., Kiupel, M., Sayadi, M., et al. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00590 · Cited by 3
Iozzo, M., Vitali, F., Chiellini, C., Gammuto, L., Taddei, A., Amedei, A., & Fani, R. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2711305 · Cited by 4
“Besides, different in vivo studies demonstrated that azurin and p28 inhibit tumor growth in 4T1 breast model, B16 melanoma and Dalton’s lymphoma ascites model [30, 32,33].”
BackgroundBacterial Protein Azurin and Tumour Suppressor P53 in Cancer Regression
Dharmawickreme, R. B. L., & Witharana, C. (2021) · Advances in Human Biology · doi:10.4103/aihb.aihb_69_20 · Cited by 4
Utilization of Cheese Whey for Production of Azurin by Pseudomonas aeruginosa
Ünver, Y. (2021) · Sakarya University Journal of Science · doi:10.16984/saufenbilder.853961 · Cited by 3
“This protein and its derived peptide p28 have anticancer activity that has been confirmed in mouse-based tumor models and various cancer cells [16, 17].”
Lu, B., Yang, H., Liu, F., Sun, Y., He, H., Ding, X., Hu, S., & Xia, L. (2020) · Research Square · doi:10.21203/rs.3.rs-27294/v4 · Cited by 3
Self-citationModulating Cardiac-Gut Microbiome Interaction Post-Myocardial Infarction with Engineered BacteriaPreprint
Madaan, T., Nieman, M. L., Rakheja, T., Siddiqui, N., Gherardini, D., Sertorio, M. G., Kamble, N. S., Thomas, S. C., Hartman, A. R., Koch, S. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.10.664025 · Cited by 4
Bacterial toxins as immunomodulatory agents in cancer therapy
Sahu, K. K., Basha, N. S., Pradhan, M., Sucheta, Dubey, A., & Yadav, K. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117309 · Cited by 2
Huang, Y. B., Zhong, Y., Lu, H., Jin, K., Zhang, Y., Yu, L., Liu, J., Zhu, X., & Wu, Y. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c17095 · Cited by 2
Self-citationSun, T., Zhang, Q., Dai, Y., Liu, Y., Teng, X., & Li, J. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124015 · Cited by 4
Liang, L., Ye, Z., Wu, J., Lu, H., Liu, W., Meng, L., Li, Y., & Huang, H. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.153977 · Cited by 2
Osawa, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198157 · Cited by 2
“Secretion of a bacterial toxin such as alpha-hemolysin (aHL) and azurin have been shown to kill cancer cells in mice [13–15].”
Magnetically controlled vector based on E coli Nissle 1917Preprint
Gorobets, S., Gorobets, O., Sharau, I., & Milenko, Y. V. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2002.01958 · Cited by 2
“Coli Nissle 1917 (EcN) has a higher ability to target the tumor, as it mainly propagates in the area between necrotic and hypoxic regions of tumors [18–20], which guarantees the penetration into the hypoxic areas of the drug, which is loaded into EcN.”
BackgroundE. Coli Nissle 1917 Based Carrier for DNA Delivery into Colorectal Carcinoma Cells
Deeb, N. E., Otinov, G. D., Mohamed, A.-A., Gandalipov, E. R., Kovtunov, E. A., & Koshel, E. I. (2024) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162024110451 · Cited by 1
Probiotics and the immune landscape: An ally in breast cancer combination therapy
Tokallou, M. A., Mahmoudi, M., Kheder, R. K., Azghadi, S. F., Rastgoo, E., Sabouri, A., & Esmaeili, S. (2025) · Nutrition · doi:10.1016/j.nut.2025.113011 · Cited by 1
Cecil, A., Gentschev, I., Prehn, C. P., Hauck, S. M., Witting, M. A., Petrov, I. S., Ye, M., Othman, E. M., & Szalay, A. A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118750 · Cited by 1
Use of in vitro co-culture models to inform bacterial engineering for the treatment of solid tumours
Foschini, S., Wright, J. A., Woods, S. L., & de Nys, R. (2026) · npj Biomedical Innovations. · doi:10.1038/s44385-026-00075-9 · Cited by 1
“EcN has been shown to selectively colonise tumours over healthy tissues in pre-clinical 14,70 and clinical studies 14 .”
Engineered probiotics for tumor-targeted combination chemoimmunotherapy
Yang, Z., Im, J., Chen, N., Mariuzza, D. L., Santos, K. D. L., Li, F., Ballister, E. R., Ringham, O. R., Danino, T., & Arpaia, N. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ady2289 · Cited by 2
Construction of Invasive Engineered Strain Targeted for Cancer Therapy Using Transposon
SiJia, T. A. N. G., Xia, L., LiMing, B. A. I., ShengBiao, H. U., XueZhi, D. I. N. G., YunJun, S. U. N., Wen, Y., & Qi, Y. A. N. G. (2015) · Scientia Sinica Vitae · doi:10.1360/n052014-00101 · Cited by 1
Self-citationTheranostic Approaches Using Live Bacteria
Min, J., Duong, M. T.-Q., Thangam, R., You, S.-H., & Kang, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00056-9 · Cited by 1
Probiotic Escherichia coli Strain Nissle 1917
Altuntaş, S., Korukluoğlu, M., & Altuntaş, V. (2017) · Pamukkale University Journal of Engineering Sciences · doi:10.5505/pajes.2017.98475 · Cited by 1
Lu, B., Yang, H., Liu, F., Sun, Y., He, H., Ding, X., Hu, S., & Xia, L. (2020) · Research Square · doi:10.21203/rs.3.rs-27294/v1 · Cited by 2
“Previous studies have demonstrated that EcN has excellent performance in preferentially localizing to tumours when administered systematically or orally to different tumour-bearing mouse models[7, 26].”
BackgroundSelf-citationExpanding the bio-capabilities of Lactococcus lactis through efficient genome modification
Rothstein, S. M. (2020) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-20210114-128
Jiang, F., Yang, H., Wang, L., Wang, Y., Tang, Y., Wang, D., Wang, Q., & Zou, J. (2021) · PubMed Central · doi:10.12122/j.issn.1673-4254.2021.05.03
Modulating Residence Time and Biogeography of Engineered Probiotics
Said, R., Mays, Z. J. S., & Nair, N. U. (2022) · Wiley eBooks · doi:10.1002/9783527825462.ch4
Lu, B., Yang, H., Liu, F., Sun, Y., He, H., Ding, X., Hu, S., & Xia, L. (2020) · Research Square · doi:10.21203/rs.3.rs-27294/v2
Self-citationLu, B., Huijun, Y., Liu, F., Sun, Y., He, H., Ding, X., Hu, S., & Xia, L. (2020) · Research Square · doi:10.21203/rs.3.rs-27294/v3 · Cited by 2
Self-citationRole of Animal Models in the Development of Bacteria-Based Live Therapeutics to Fight Cancer
Tata, K., Ramadevi, S., Shelin, R., & Meenakshi, S. (2022) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-1282-5_7-1
Role of Animal Models in the Development of Bacteria-Based Live Therapeutics to Fight Cancer
Tata, K., Ramadevi, S., Shelin, R., & Meenakshi, S. (2023) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-3824-5_7
Mousa, W. K., Ali, A., Abdelmoteleb, R. W. A., Shami, R. A., Alramadan, N., Moutraji, S. A., & Ghemrawi, R. (2025) · Targeted Cancer Therapy Connect · doi:10.69709/ciconnect.2025.154988
Othman, E. M. (2025) · Research Square · doi:10.21203/rs.3.rs-6990456/v1
Intratumoral microbiota: Distribution, mechanisms, and therapeutic implications
Ge, J., Gao, L., & Yu, L. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105128 · Cited by 1
Li, X., Chang, J., Xia, Q., Yan, J., Zhang, H., & Yang, H. (2026) · Microorganisms · doi:10.3390/microorganisms14040807
“E. coli Nissle 1917 was engineered to express the redox protein azurin, which inhibited melanoma and other cancer cell growth [174].”
Li, X., Ding, S., Yang, B., Wang, Y., & Xie, W. (2026) · RSC Advances · doi:10.1039/d5ra09644h
Mohammed, O. A., Awlqadr, F. H., Faraj, A. M., Qadir, S. A., Morya, S., & Saeed, M. N. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12302-y
“In another study, minicells of engineered E. coli Nissle expressing azurin inhibited tumor growth in vivo with an absence of apparent systemic side effects [ 78].”
Azurins With Tunable Reduction Potentials as Redox Mediators for Extracellular Electron Transfer
Holwerda, A. J., Wang, J.-X., Gao, Y., Lu, Y., & Keitz, B. K. (2026) · ChemBioChem · doi:10.1002/cbic.70477
“Though this may present some challenges, azurin has been successfully expressed for whole-cell use in Escherichia coli Nissle 1917 [70].”
Deeb, N., Otinov, G. D., & Koshel, E. I. (2026) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162026602120
Wang, X., Wang, Y., Wu, D., Kang, Y., Li, R., Yang, G., Chen, G., Chen, Z., Hong, W., & Cui, G. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11234-0
Deeb, N., Otinov, G., Tikhomirov, A., Mouhammad, E., Savin, A., & Koshel, E. I. (2026) · Applied Microbiology · doi:10.3390/applmicrobiol6100126
Metadata
- Authors
- Zhang, Y., Zhang, Y., Xia, L., Zhang, X., Ding, X., Yan, F., & Wu, F.
- Affiliations
- Hunan Normal University (CN)
- College of Life Science, Hunan Provincial Key Laboratory of Microbial Molecular Biology—State Key Laboratory Breeding Base of Microbial Molecular Biology, Hunan Normal University, Changsha, China
- Venue
- Applied and Environmental Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2012-11
- Volume
- 78
- Issue
- 21
- Pages
- 7603-7610
- ISSN
- 0099-2240 (ISSN-L)
- 1098-5336
- PMC
- PMC3485711
- OpenAlex
- W1964108510
- Cited by
- 138
- References
- 46
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 14 · 2023: 12 · 2022: 16 · 2021: 15 · 2020: 18 · 2019: 6 · 2018: 8 · 2017: 8 · 2016: 4 · 2015: 2 · 2014: 5 · 2013: 2
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Applied and Environmental Microbiology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- Escherichia coli Nissle 1917, azurin, tumor-targeting bacteria, B16 melanoma, 4T1 breast cancer, tumor growth inhibition, lung metastasis, neutrophils, lymphocytes, inflammation, bacterial drug delivery, cancer therapy, recombinant protein expression
- MeSH terms
- Animals, Antineoplastic Agents, Azurin, Disease Models, Animal, Escherichia coli, Female, Genetic Engineering, Lung Neoplasms, Mammary Neoplasms, Experimental, Melanoma, Experimental, Mice, Inbred BALB C, Plasmids, Drug Delivery Systems, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.